Tezosentan in the Treatment of Acute Heart Failure

Annals of Pharmacotherapy

Volumn 37, Issue 12, 2003, Pages 1877-1883

  Tovar, John M ^a   Gums, John G ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

Endothelin 1; Heart failure; RITZ; Tezosentan

Indexed keywords

ENDOTHELIN RECEPTOR ANTAGONIST; TEZOSENTAN;

ACUTE HEART FAILURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EVALUATION; HALF LIFE TIME; HEADACHE; HUMAN; HYPOTENSION; KIDNEY FAILURE; MEDLINE; NAUSEA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; STEADY STATE; VOMITING;

ACUTE DISEASE; ANIMALS; CLINICAL TRIALS; HEART FAILURE, CONGESTIVE; HUMANS; PYRIDINES; TETRAZOLES;

EID: 0344412963     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1D080     Document Type: Review

References (39)

1. 2003 Heart and stroke statistical update. Dallas: American Heart Association, 2002.
2. 2001 Heart and stroke statistical update. Dallas: American Heart Association, 2000.
3. Fonarow GC. The treatment targets in acute decompensated heart failure. Rev Cardiovasc Med 2001;2(suppl 2):S7-12.
4. O'Connor CM, Gattis WA, Adams KF, Shah MR, Kobrin I, Frey A, et al. Tezosentan in patients with acute heart failure and acute coronary syndromes: design of the Randomized Intravenous Tezosentan Study (RITZ-4). Am Heart J 2002;144:583-8.
5. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993;328:1732-9.
6. Lüscher TM, Barton M. Endothelins and endothelin receptor antagonists. Circulation 2000;102:2434-40.
7. McMurray JJ, Ray SG, Abdullah I, Dargie HJ, Morton JJ. Plasma endothelin in chronic heart failure. Circulation 1992;85:1374-9.
8. Clozel M, Qiu C, Qiu CS, Hess P, Clozel JP. Short-term endothelin receptor blockade with tezosentan has both immediate and long-term beneficial effects in rats with myocardial infarction. J Am Coll Cardiol 2002;39:142-7.
9. Chin A, Radhakrishnan J, Fornell L, John E. Effects of tezosentan, a dual endothelin receptor antagonist, on the cardiovascular and renal systems of neonatal piglets during endotoxic shock. J Pediatr Surg 2002;37:482-7.
10. Wilhelm SM, Stowe NT, Robinson AV, Schulak JA. The use of the endothelin receptor antagonist, tezosentan, before or after renal ischemia protects renal function. Transplantation 2001;71:211-6.
11. Clozel M, Ramuz H, Clozel JP, Breu V, Hess P, Löffler B, et al. Pharmacology of tezosentan, new endothelin receptor antagonist designed for parenteral use. J Pharmacol Exp Ther 1999;290:840-6.
12. Levin ER. Endothelins. N Engl J Med 1995;333:356-63.
13. Love MP, Haynes WG, Webb DJ, McMurray JJ. Venous endothelin receptor function in patients with chronic heart failure. Clin Sci 2000;98:65-70.
14. Kaur S, Frishman WH, Singh I, Tamirisa P, Kumar A. Endothelin as a therapeutic target in the treatment of cardiovascular disease. Heart Dis 2001;3:176-88.
15. Sütsch G, Kiowski W, Yan XW, Hunziker P, Christen S, Strobel W, et al. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation 1998;98:2262-8.
16. Sakai S, Miyauchi T, Kobayashi M, Yamaguchi I, Goto K, Sugishita Y. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature 1996;384:353-5.
17. Borgeson DD, Grantham JA, Williamson EE, Luchner A, Redfield MM, Opgenorth TJ, et al. Chronic oral endothelin type A receptor antagonism in experimental heart failure. Hypertension 1998;31:766-70.
18. Qiu CB, Qiu CS, Hess P, Clozel JP, Clozel M. Additional effects of endothelin receptor blockade and angiotensin converting enzyme inhibition in rats with chronic heart failure. Acta Pharmacol Sin 2001;22:541-8.
19. Qiu C, Ding SS, Hess P, Clozel JP, Clozel M. Endothelin mediates the altered renal hemodynamics associated with experimental congestive heart failure. J Cardiovasc Pharmacol 2001;38:317-24.
20. Li JS, Schiffrin EL. Effect of chronic treatment of adult spontaneously hypertensive rats with an endothelin antagonist. Hypertension 1995;25:495-500.
21. Li JS, Knafo L, Turgeon A, Garcia R, Schiffrin EL. Effect of endothelin antagonism on blood pressure and vascular structure in renovascular hypertensive rats. Am J Physiol 1996;271(1 pt 2):H88-93.
22. Dingemanse J, Clozel M, Van Giersbergen P. Entry-into-humans study with tezosentan, an intravenous dual endothelin receptor antagonist. J Cardiovasc Pharmacol 2002;39:795-802.
23. Dingemanse J, Clozel M, Van Giersbergen P. Pharmacokinetics and pharmacodynamics of tezosentan, an intravenous dual endothelin receptor antagonist, following chronic infusion in healthy subjects. Br J Clin Pharmacol 2002;53:355-62.
24. Treiber A, Van Giersbergen PL, Dingemanse J. In vivo and in vitro disposition profile of tezosentan, an intravenous dual endothelin receptor antagonist, in humans. Xenobiotica 2003;33:399-414.
25. Van Giersbergen P, Bodin F, Dingemanse J. Cyclosporine increases the exposure to tezosentan, an intravenous dual endothelin receptor antagonist. Eur J Clin Pharmacol 2002;58:243-5.
26. Torre-Amione G, Young JB, Durand JB, Bozkurt B, Mann DL, Kobrin I, et al. Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure. Circulation 2001;103:973-80.
27. Schalcher C, Cotter G, Reisin L, Bertel O, Kobrin I, Guyene T, et al. The dual endothelin antagonist tezosentan acutely improves hemodynamic parameters in patients with advanced heart failure. Am Heart J 2001;142:340-9.
28. Coletta AP, Cleland J. Clinical trials update: Highlights of the Scientific Sessions of the XXIII Congress of the European Society of Cardiology - WARIS II, ESCAMI, PAFAC, RITZ-1 and TIME. Eur J Heart Fail 2001;3:747-50.
29. Louis A, Cleland J, Crabbe S, Ford S, Thackray S, Houghton T, et al. Clinical trials update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001. Eur J Heart Fail 2001;3:381-7.
30. Bahit MC, Cabell CH, Dyke CK, Felker GM, Kaul P, McGuire DK, et al. Highlights from the American College of Cardiology Forty-Ninth Annual Scientific Sessions: March 18-21, 2001. Am Heart J 2001;142:363-74.
31. Lyford J. Selected highlights from the 50th Annual Scientific Session of the American College of Cardiology, Orlando, USA, 18-21 March 2001. Curr Control Trials Cardiovasc Med 2001;2:85-9.
32. Fonarow GC. Best of the AHA Scientific Sessions 2001. Rev Cardiovasc Med 2002;3:23-6.
33. O'Connor CM, Gattis WA, Adams KF, Hasselblad V, Chandler B, Frey A, et al. Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4). J Am Coll Cardiol 2003;41:1452-7.
34. Kaluski E, Kobrin I, Zimlichman R, Mannor A, Krakov O, Milo O, et al. RITZ-5: Randomized Intravenous TeZosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema. J Am Coll Cardiol 2003;41:204-10.
35. Cotter G, Kiowski W, Kaluski E, Kobrin I, Milovanov O, Marmor A, et al. Tezosentan (an intravenous endothelin receptor A/B antagonist) reduces peripheral resistance and increases cardiac power therefore preventing a steep decrease in blood pressure in patients with congestive heart failure. Eur J Heart Fail 2001;3:457-61.
36. Colucci W, Elkayam U, Horton PH, Abraham WT, Bourge RC, Johnson AD, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med 2000;343:246-53.
37. Torre-Amione G, Durand J, Nagueh S, Vooletich MT, Kobrin I, Pratt C. A pilot safety trial of prolonged (48 h) infusion of the dual endothelin-receptor antagonist tezosentan in patients with advanced heart failure. Chest 2001;120:460-6.
38. Kurihara Y, Kurihara H, Suzuki H, Kodama T, Maemura K, Nagai R, et al. Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1. Nature 1994;368:703-10.
39. Clinical Pharmacology Online (bosentan monograph). Gold Standard Multimedia, Tampa, 2003. www.cpip.gsm.com (accessed 2002 Dec 4).